225 related articles for article (PubMed ID: 23738762)
21. Best immunohistochemical panel in distinguishing adenocarcinoma from squamous cell carcinoma of lung: tissue microarray assay in resected lung cancer specimens.
Kim MJ; Shin HC; Shin KC; Ro JY
Ann Diagn Pathol; 2013 Feb; 17(1):85-90. PubMed ID: 23040737
[TBL] [Abstract][Full Text] [Related]
22. Is the current diagnostic algorithm reliable for selecting cases for EGFR- and KRAS-mutation analysis in lung cancer?
Vincenten JP; Smit EF; Grünberg K; Postmus PE; Snijders PJ; Witte BI; Heideman DA; Thunnissen E
Lung Cancer; 2015 Jul; 89(1):19-26. PubMed ID: 25982011
[TBL] [Abstract][Full Text] [Related]
23. Dissecting Pulmonary Large-Cell Carcinoma by Targeted Next Generation Sequencing of Several Cancer Genes Pushes Genotypic-Phenotypic Correlations to Emerge.
Pelosi G; Fabbri A; Papotti M; Rossi G; Cavazza A; Righi L; Tamborini E; Perrone F; Settanni G; Busico A; Testi MA; Maisonneuve P; De Braud F; Garassino M; Valeri B; Sonzogni A; Pastorino U
J Thorac Oncol; 2015 Nov; 10(11):1560-9. PubMed ID: 26317919
[TBL] [Abstract][Full Text] [Related]
24. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.
Kim HR; Shim HS; Chung JH; Lee YJ; Hong YK; Rha SY; Kim SH; Ha SJ; Kim SK; Chung KY; Soo R; Kim JH; Cho BC
Cancer; 2012 Feb; 118(3):729-39. PubMed ID: 21720997
[TBL] [Abstract][Full Text] [Related]
25. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.
Cai G; Wong R; Chhieng D; Levy GH; Gettinger SN; Herbst RS; Puchalski JT; Homer RJ; Hui P
Cancer Cytopathol; 2013 Sep; 121(9):500-7. PubMed ID: 23495083
[TBL] [Abstract][Full Text] [Related]
26. Molecular alterations in non-small cell lung carcinomas of the young.
VandenBussche CJ; Illei PB; Lin MT; Ettinger DS; Maleki Z
Hum Pathol; 2014 Dec; 45(12):2379-87. PubMed ID: 25288236
[TBL] [Abstract][Full Text] [Related]
27. Ly6/uPAR-related protein C4.4A as a marker of solid growth pattern and poor prognosis in lung adenocarcinoma.
Jacobsen B; Muley T; Meister M; Dienemann H; Christensen IJ; Santoni-Rugiu E; Lærum OD; Ploug M
J Thorac Oncol; 2013 Feb; 8(2):152-60. PubMed ID: 23287851
[TBL] [Abstract][Full Text] [Related]
28. EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype.
Warth A; Penzel R; Lindenmaier H; Brandt R; Stenzinger A; Herpel E; Goeppert B; Thomas M; Herth FJ; Dienemann H; Schnabel PA; Schirmacher P; Hoffmann H; Muley T; Weichert W
Eur Respir J; 2014 Mar; 43(3):872-83. PubMed ID: 23988776
[TBL] [Abstract][Full Text] [Related]
29. A comparison of EGFR and KRAS status in primary lung carcinoma and matched metastases.
Monaco SE; Nikiforova MN; Cieply K; Teot LA; Khalbuss WE; Dacic S
Hum Pathol; 2010 Jan; 41(1):94-102. PubMed ID: 19740513
[TBL] [Abstract][Full Text] [Related]
30. Large cell carcinoma of the lung: a tumor in search of an author. A clinically oriented critical reappraisal.
Pelosi G; Barbareschi M; Cavazza A; Graziano P; Rossi G; Papotti M
Lung Cancer; 2015 Mar; 87(3):226-31. PubMed ID: 25620799
[TBL] [Abstract][Full Text] [Related]
31. Napsin-A, TTF-1, EGFR, and ALK Status Determination in Lung Primary and Metastatic Mucin-Producing Adenocarcinomas.
Rossi G; Cavazza A; Righi L; Sartori G; Bisagni A; Longo L; Pelosi G; Papotti M
Int J Surg Pathol; 2014 Aug; 22(5):401-7. PubMed ID: 24651909
[TBL] [Abstract][Full Text] [Related]
32. Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients.
Fathi Z; Mousavi SAJ; Roudi R; Ghazi F
PLoS One; 2018; 13(7):e0200633. PubMed ID: 30048458
[TBL] [Abstract][Full Text] [Related]
33. Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study.
McLeer-Florin A; Moro-Sibilot D; Melis A; Salameire D; Lefebvre C; Ceccaldi F; de Fraipont F; Brambilla E; Lantuejoul S
J Thorac Oncol; 2012 Feb; 7(2):348-54. PubMed ID: 22071784
[TBL] [Abstract][Full Text] [Related]
34. TTF-1, cytokeratin 7, 34betaE12, and CD56/NCAM immunostaining in the subclassification of large cell carcinomas of the lung.
Rossi G; Marchioni A; Milani M; Scotti R; Foroni M; Cesinaro A; Longo L; Migaldi M; Cavazza A
Am J Clin Pathol; 2004 Dec; 122(6):884-93. PubMed ID: 15595193
[TBL] [Abstract][Full Text] [Related]
35. Five-year survival and prognostic factors according to histology in 6101 non-small-cell lung cancer patients.
Molinier O; Goupil F; Debieuvre D; Auliac JB; Jeandeau S; Lacroix S; Martin F; Grivaux M
Respir Med Res; 2020 Mar; 77():46-54. PubMed ID: 32036284
[TBL] [Abstract][Full Text] [Related]
36. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization.
Paik JH; Choe G; Kim H; Choe JY; Lee HJ; Lee CT; Lee JS; Jheon S; Chung JH
J Thorac Oncol; 2011 Mar; 6(3):466-72. PubMed ID: 21258247
[TBL] [Abstract][Full Text] [Related]
37. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose.
Li H; Pan Y; Li Y; Li C; Wang R; Hu H; Zhang Y; Ye T; Wang L; Shen L; Sun Y; Chen H
Lung Cancer; 2013 Jan; 79(1):8-13. PubMed ID: 23098378
[TBL] [Abstract][Full Text] [Related]
38. Molecular dissection of large cell carcinomas of the lung with null immunophenotype.
Harms A; Endris V; Winter H; Kriegsmann M; Stenzinger A; Schirmacher P; Warth A; Kazdal D
Pathology; 2018 Aug; 50(5):530-535. PubMed ID: 29958730
[TBL] [Abstract][Full Text] [Related]
39. Epidermal growth factor receptor and Kras gene expression: reliability of mutational analysis on cytological samples.
Bozzetti C; Negri FV; Azzoni C; Naldi N; Nizzoli R; Bortesi B; Zobbi V; Bottarelli L; Tiseo M; Silini EM; Ardizzoni A
Diagn Cytopathol; 2013 Jul; 41(7):595-8. PubMed ID: 22833420
[TBL] [Abstract][Full Text] [Related]
40. Activation status of receptor tyrosine kinase downstream pathways in primary lung adenocarcinoma with reference of KRAS and EGFR mutations.
Hiramatsu M; Ninomiya H; Inamura K; Nomura K; Takeuchi K; Satoh Y; Okumura S; Nakagawa K; Yamori T; Matsuura M; Morikawa T; Ishikawa Y
Lung Cancer; 2010 Oct; 70(1):94-102. PubMed ID: 20117855
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
